Setback: AstraZeneca proposal to market, manufacture Olaparib rejected by CDSCO panel Dr. Divya Colin23 April 2022 5:03 PM ISTNew Delhi: In a major setback to AstraZeneca, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has...
AstraZeneca India rebrands Global Technology Centre as Global Innovation and Technology Centre Ruchika Sharma8 April 2022 1:05 PM ISTThe rebranding marks the centre's evolution of capabilities, commitment to driving innovation and moving the company towards a digitally-enabled...
MoS Health Tells Rajya Sabha :Increase in Antibodies Post Covaxin Booster Dose Medical Dialogues Bureau31 March 2022 4:40 PM ISTNew Delhi: An ICMR study to examine the effect of Covaxin's booster dose has shown an increase in the levels of antibodies against SARS-CoV-2,...
AstraZeneca Evusheld recommended for approval in EU for prevention of COVID Ruchika Sharma27 March 2022 9:30 AM ISTThe recommended dose of Evusheld in Europe is 150 mg of tixagevimab and 150mg of cilgavimab, administered as two separate sequential intramuscular...
Bristol Myers sues AstraZeneca over cancer-treatment patents MD Bureau19 March 2022 6:08 PM ISTBristol asked the Delaware court for an undisclosed amount of monetary damages.
Mylan Pharma gets USFDA nod for Breyna for Generic Version of Symbicort MD Bureau17 March 2022 3:29 PM ISTViatris Inc. and Kindeva Drug Delivery L.P. today announced that Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug...
No USFDA approval for AstraZeneca's treatment for chronic nasal condition MD Bureau15 March 2022 3:02 PM ISTThe London-listed drugmaker said the U.S. Food and Drug Administration (FDA) had issued a complete response letter following AstraZeneca's application...
AstraZeneca's Young Health Program opens 3 Health Information Centres (HICs) in Bangalore MD Bureau12 March 2022 3:00 PM ISTThe three HICs at Mahadevpura, Dasarahalli and Yelahanka are developed under Astrazeneca's flagship CSR initiative 'Young Health Programme' that aims...
ISN and AstraZeneca announce multi-year partnership for KCD MD Bureau9 March 2022 2:35 PM ISTChronic Kidney Disease (CKD) today has become a major cause of global mortality and morbidity.
AstraZeneca and Neurimmune collaborate to develop and commercialize NI006 MD Bureau2 March 2022 1:15 PM ISTNI006 is an investigational human monoclonal antibody that specifically targets misfolded transthyretin.
AstraZeneca, Honeywell to collaborate to develop next-generation respiratory inhalers MD Bureau25 Feb 2022 3:02 PM ISTUK: AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less...
Positive result of Enhertu in DESTINY-Breast04 trial: AstraZeneca Ruchika Sharma22 Feb 2022 11:30 AM ISTUK: In a significant development, AstraZeneca has announced the positive high-level results from the pivotal DESTINY-Breast04 Phase III...
